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Abstract
Background: Defective iron homeostasis may be involved in the development of some diseases
within the central nervous system. Although the expression of genes involved in normal iron
balance has been intensively studied in other tissues, little is known about their expression in the
brain. We investigated the mRNA levels of hepcidin (HAMP), HFE, neogenin (NEO1), transferrin
receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) in normal human brain,
brain tumors, and astrocytoma cell lines. The specimens included 5 normal brain tissue samples, 4
meningiomas, one medulloblastoma, 3 oligodendrocytic gliomas, 2 oligoastrocytic gliomas, 8
astrocytic gliomas, and 3 astrocytoma cell lines.
Results: Except for hemojuvelin, all genes studied had detectable levels of mRNA. In most tumor
types, the pattern of gene expression was diverse. Notable findings include high expression of
transferrin receptor 1 in the hippocampus and medulla oblongata compared to other brain regions,
low expression of HFE in normal brain with elevated HFE expression in meningiomas, and absence
of hepcidin mRNA in astrocytoma cell lines despite expression in normal brain and tumor
specimens.
Conclusion: These results indicate that several iron-related genes are expressed in normal brain,
and that their expression may be dysregulated in brain tumors.
Background
Regulation of iron homeostasis is crucial to maintain nor-
mal cell function, and abnormal cellular iron content has
been associated with various diseases. Iron is an essential
cofactor for many proteins particularly in oxidative reac-
tions and, therefore, neuronal tissues with a high rate of
oxidative metabolism have a considerable requirement
for iron [1]. The central nervous system (CNS) is not
directly in contact with the plasma iron pool, because it
resides behind the blood-brain barrier. Like many mole-
cules, the entry of iron is tightly regulated by the blood-
brain barrier, and specific transport mechanisms are
required to transfer iron into the brain tissue [2]. Several
gene products involved in the regulation of iron homeos-
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rin receptor 1 (TfR1) [3], iron regulatory protein [4],
ferritin [3], neogenin [5], and hepcidin [6]. Even though
iron has an essential role for normal physiology, it poses
a threat to cells and tissues when present in excess. This
feature is based on iron's ability to readily participate in
oxidation-reduction reactions and the formation of reac-
tive oxygen intermediates [1]. Iron accumulation has been
reported in the nervous tissue of patients suffering from
various neurodegenerative disorders, including Alzhe-
imer's disease, Parkinson's disease, amyotrophic lateral
sclerosis and age-related macular degeneration [7-10].
Malignant CNS tumors arise worldwide in approximately
189,000 patients per year with an estimated annual mor-
tality of 142,000 [11]. Malignant gliomas, including the
most common subtype, glioblastoma, are among the
most devastating neoplasms and still pose a great chal-
lenge for both diagnosis and treatment. Malignant glio-
mas derive from glial cells and exhibit aggressive tumor
characteristics such as high proliferation rate, diminished
apoptosis, and escape from external growth control. A dis-
tinctive feature of gliomas is that they very rarely metasta-
size beyond the CNS, despite their highly invasive and
angiogenic capabilities [12].
In neoplastic tissues, the oxygen requirement is high, and
thus angiogenesis is often crucial for cancer survival. For
malignant CNS tumors, especially gliomas, neovasculari-
zation is directly correlated with their biological aggres-
siveness, degree of malignancy and clinical recurrence,
and is inversely correlated with post-operative survival
time [13]. Neovascularization is driven by a complex reg-
ulatory pathway involving von Hippel-Lindau protein
(pVHL) and hypoxia-inducible factor (HIF). In normoxia,
the transcription factor HIF is targeted for proteosomal
degradation, whereas it is stabilized in hypoxic condi-
tions. HIF accumulation induces the expression of several
proangiogenic proteins, including transferrin and TfR1,
that are linked to the regulation of cellular iron homeos-
tasis [13].
Hepcidin is a key regulator of iron homeostasis that is
abundantly expressed in the liver [14,15]. Iron overload
leads to increased hepcidin synthesis, while anaemia,
hypoxia, and inflammation downregulate its expression
[16]. A recent study showed that hypoxia downregulates
hepcidin expression via the VHL/HIF pathway [17]. Hep-
cidin acts by modulating the activity of ferroportin, the
only iron export protein known to exist in mammalian
cells. By binding to ferroportin, hepcidin causes its inter-
nalization and degradation and, thereby, decreases cellu-
lar iron export [18]. Hemojuvelin and its putative co-
regulator, neogenin, are other factors that may be
involved in the regulation of hepcidin expression [19-21].
Because malignant cells have a high metabolic rate and
require significant quantities of iron for various cellular
processes, our hypothesis was that iron related genes are
differentially expressed in brain tumor cells versus normal
brain tissue. The goal of this study was to investigate the
expression levels of genes related to iron homeostasis in
both brain tumors and normal brain regions. The mRNA
expression levels of hepcidin (HAMP), HFE, neogenin
(NEO1), transferrin receptor 1 (TFRC), transferrin recep-
tor 2 (TFR2), and hemojuvelin (HFE2) were measured.
We found that all the studied genes, except for hemojuve-
lin, were expressed in normal brain, and altered expres-
sion patterns were found in brain tumors and astrocytoma
cell lines. The results suggest that these genes might play a
role in the maintenance of iron homeostasis in the brain,
and their differential expression in brain tumors may con-
tribute to tumor pathogenesis.
Methods
Study materials for RNA isolation
The study material consisted of: 1) 18 brain tumors
obtained as histopathology samples from surgical
patients in Tampere University Hospital, Tampere, Fin-
land between 1983 and 2001 (Table 1); 2) 5 samples of
normal brain tissue, and 3) 3 astrocytoma cell lines. The
experiments were approved by the Ethical Committee of
the Tampere University Hospital and conducted accord-
ing to the guidelines of the Helsinki Declaration. The
brain tumors comprised 4 meningiomas (2 grade II; 2
grade III), 3 oligodendrocytic gliomas (2 grade II; 1 grade
III), 2 oligoastrocytic gliomas (1 grade II; 1 grade III), one
Table 1: Patient information for brain tumor samples
Patient Type of tumor Stage Age at diagnosis Sex
1 Meningioma I 72 F
2 Meningioma I 62 F
3 Meningioma II 86 F
4 Meningioma II 27 M
5 Oligodendroglioma II 54 F
6 Oligodendroglioma II 47 M
7 Oligodendroglioma III 59 M
8 Oligoastrocytoma II 44 F
9 Oligoastrocytoma III 40 M
10 Medulloblastoma IV 19 F
11 Astrocytoma I 21 M
12 Astrocytoma II 26 M
13 Astrocytoma II 44 F
14 Astrocytoma III 44 M
15 Astrocytoma III 51 F
16 Astrocytoma III 61 F
17 Astrocytoma III 44 M
18 Astrocytoma IV 62 MPage 2 of 9
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(grade I), and 7 diffusively infiltrating astrocytic gliomas
(2 grade II; 4 grade III; 1 grade IV). The age of the patients
ranged from 19 to 86 years (48 ± 18, mean ± SD). Normal
brain tissue was obtained post-mortem upon autopsy,
and included samples of cortex, cerebellum, thalamus,
medulla oblongata, and hippocampus. The cell lines,
CCF-STTG1, U373 MG, and U-87 MG, were originally
derived from grade IV astrocytomas (glioblastomas).
These cell lines were obtained from the European Collec-
tion of Cell Cultures (Salisbury, UK) and were cultured
according to the provider's instructions.
Statistical analysis
Spearman's rank correlation coefficient was used to deter-
mine the influence of age on expression levels. The results
were considered statistically significant when the correla-
tion coefficient was < -0.300 or > 0.300, with p-value <
0.05. Mann-Whitney U test was used to evaluate the effect
of sex on the expression levels. The results were consid-
ered statistically significant when p-value was < 0.05.
RNA isolation and first-strand cDNA synthesis
All tissue specimens to be used for RNA isolation were
placed in RNAlater (Ambion, Austin, TX) and stored at -
80°C until use. Total RNA was isolated from tissue sam-
ples using QIAzol lysis reagent and RNeasy Lipid Tissue
Mini Kit (Qiagen, Germantown, MD) and from cell cul-
tures using RNeasy Mini Kit (Qiagen) following the man-
ufacturer's instructions. Both protocols included
treatment with RNase-free DNase I (Novagen, Madison,
WI). RNA concentration and purity were determined by
optical density measurement at 260 and 280 nm. All the
samples had an OD260/OD280 ratio of 2.0 or higher. For
each sample, 0.6 μg of total RNA were converted into first-
strand cDNA using the First-Strand cDNA Synthesis Kit
(Fermentas, Burlington, Canada) and oligo d(T) primers
according to the protocol recommended by the manufac-
turer.
Reverse transcription PCR and quantitative real-time PCR
The relative amounts of human HAMP, HFE, NEO1,
TFRC, and TFR2 transcripts in different tissues were first
assessed by reverse transcription (RT) PCR and then with
quantitative real-time PCR using the LightCycler detection
system (Roche, Rotkreuz, Switzerland). HFE2 expression
was studied only by RT-PCR which remained completely
negative. The RT-PCR and the real-time PCR primers for
the target transcripts were designed using the complete
cDNA sequences deposited in GenBank (accession num-
bers: NM_000410 for HFE, NM_021175 for HAMP,
NM_003234 for TFRC, NM_003227 for TFR2,
NM_002499 for NEO1 and NM_213653 for HFE2). To
avoid amplification of contaminating genomic DNA, the
two primers from each primer set were placed in different
exons. HPRT1 (hypoxanthine phosphoribosyl-transferase
I), GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
TBP (TATA box binding protein), and UBC (ubiquitin C)
were used as internal controls to normalize for potential
quality and quantity differences between samples.
According to study of Vandesompele et al. four internal
control genes are required for accurate normalization of
the samples [22]. The internal control transcripts and
primer sequences for HPRT1, GAPDH, UBC were chosen
based on the results of Vandesompele et al. [22]. Table 2
shows the primer sequences used to measure the internal
control transcripts and the target transcripts.
PCR reactions were performed using ReddyMix PCR Mas-
ter Mix (ABgene, UK) according to manufacturer's instruc-
tions. B2M (beta-2-microglobulin) was used as positive
control for the RT-PCR reactions. The PCR products were
visualized by gel electrophoresis in 1.5% agarose gel with
0.1 μL/mL ethidium bromide. Quantitative real-time PCR
reactions were carried out in a 20 μL volume containing
0.5 μL of first strand cDNA, 1× of QuantiTect SYBR Green
PCR Master Mix (Qiagen, Hilden, Germany), and 0.5 μM
of forward and reverse primers. Amplification and detec-
tion were carried out as follows. After an initial 15-min
Table 2: Primer sequences for quantitative real-time PCR
Gene Forward primer (5'-3') Reverse promer (5'-3')
HPRT1* TGACACTGGCAAAACAATGCA GGTCCTTTCACCACAAGCT
GAPDH* TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
UBC* ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA
HFE CAACAAGTGCCTCCTTTGGT GGGGGTACAGCCAAGGTTAT
HAMP CCACAACAGACGGGACAAC CTTGCAGCACATCCCACAC
NEO1 GCTGGAAGGCGAGGAATGA CGGGTGGTAGAGATGACTG
TFRC CTTTGGACATGCTCATCTGG TGTTTTCCAGTCAGAGGGACA
TFR2 TGGAGGACACCATCAGGCAA AGCTGCTCTCCGACCTTCC
HFE2** GGAGAATTGGATAGCAGAG AGCAGCAGGAGAGTGAGA
B2M** TCCAGCGTACTCCAAAGATTCAGG ATGCGGCATCTTCAAACCTCC
* Primer sequences first described in [22]
** Primers used for RT-PCR onlyPage 3 of 9
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tion at 94°C, 15 s; annealing at Tm, 20 s; elongation at
72°C, 20 s, and final cooling step. Melting curve analysis
was always performed after the amplification to check
PCR specificity. To quantify the concentration of both the
internal control transcripts and the transcripts for HAMP,
HFE, NEO1, TFRC, and TFR2 in the samples, a standard
curve for each transcript was established using 5-fold
serial dilutions of known concentrations of purified PCR
products generated from the same primer sets. Each cDNA
sample was tested in triplicate. Replicate analyses were
automatically handled by the software of the real-time
PCR machine. The crossing point value obtained was uti-
lized to determine the amount of original transcript using
the specific standard curve. The geometric mean of the 4
internal control transcripts was used as a normalization
factor for gene expression levels [22]. The final relative
mRNA expression was designated as the copy number of
a target transcript in each tissue divided by the corre-
sponding normalization factor and subsequently multi-
plied by 102 or 103.
Results and discussion
In this study, the mRNA expression levels of hepcidin
(HAMP), HFE, neogenin (NEO1), TfR1 (TFRC), transfer-
rin receptor 2 (TFR2), and hemojuvelin (HFE2) were
examined in normal human brain tissue, brain tumors,
and astrocytoma cell lines. Hemojuvelin showed no
expression in RT-PCR experiments and, therefore, it was
not analyzed further by quantitative real-time PCR.
The statistical analysis revealed no significant influence of
either age or sex on the expression levels of genes studied.
Hepcidin (HAMP) showed relatively high expression lev-
els in all brain regions examined (Fig. 1); the highest
expression was found in the cortex and thalamus. Previ-
ously, hepcidin expression has been demonstrated in
murine brain [6], but it appears to be absent in the catfish
Hepcidin mRNA expression in normal brain and brain tumors detected by real-time PCRFigure 1
Hepcidin mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is nor-
malized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cor-
tex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to 
Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers 
in astrocytomas indicate tumor grade.Page 4 of 9
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cidin mRNA is produced in mammalian brain tissue
where the encoded hepcidin peptide may contribute to
iron homeostasis as well as to mechanisms protecting the
CNS from microbial infections. Most tumor samples had
lower expression of hepcidin compared to normal brain
cortex, and the levels were negligible in the astrocytoma
cell lines (Fig. 1). The absence of hepcidin mRNA in the
astrocytoma cell lines was surprising because it was
expressed in most tissue specimens. One explanation
could be that some non-neuronal/non-glial cells such as
endothelial cells might be the predominant site of hepci-
din expression in the brain. However, this is unlikely
because Zechel et al. [6] have reported hepcidin expres-
sion in both neurons and glia cells. It is important to real-
ize that the cell lines were cultured in optimized and
normoxic conditions, while the hypoxia is the key regula-
tor of variable genes in tumors growing in the hostile envi-
ronment [13,24]. Although the exact molecular
mechanisms remain unclear, intratumoral factors includ-
ing paracrine regulation might contribute to the unex-
pected expression pattern of hepcidin. Cultured cells may
be lacking some key factors which induce intratumoral
hepcidin expression. Previous studies have identified sev-
eral factors that regulate hepcidin mRNA expression in the
liver. For example, iron overload increases hepcidin
expression, whereas anemia and hypoxia lead to down-
regulation [25]. Hypoxia acting through a VHL/HIF-
induced pathway induces the expression of several genes
in tumors which, in turn, may increase the resistance of
tumor cells to their hostile microenvironment [26,27].
Peyssonnaux et al. [17] recently showed that a VHL/HIF
pathway regulates hepatic hepcidin expression in vivo, but
the potential role of this pathway in modulating brain
hepcidin is unknown.
Hemojuvelin also plays an important role in hepcidin reg-
ulation in the liver, acting as a co-receptor for bone mor-
phogenetic protein [20]. Hemojuvelin exists in both
membrane-bound and soluble forms, and Silvestri et al.
[28] have demonstrated regulation of soluble hemojuve-
lin via HIF-1α and furin. However, our results indicate
that hemojuvelin mRNA is not expressed in normal brain
tissue or in brain tumors. A previous study demonstrated
that murine brain also does not express hemojuvelin [5].
Taken together, the available data suggest that hemojuve-
lin may not regulate hepcidin expression in the brain, or
soluble hemojuvelin produced elsewhere is transferred
across the blood-brain barrier to regulate hepcidin expres-
sion in the brain.
Neogenin has been demonstrated to interact with hemo-
juvelin, and it has been hypothesized that, through this
interaction, neogenin may influence hepcidin expression
[19,21,29]. A previous report has shown that neogenin is
expressed widely in murine tissues, including the brain
[5]. We observed that neogenin mRNA is abundant in
normal human brain tissue, and the highest expression
levels were found in the medulla oblongata and hippoc-
ampus (Fig. 2). In contrast, neogenin mRNA levels were
low in oligodendrogliomas, oligoastrocytomas, medul-
loblastomas, and astrocytomas, while in meningiomas
and astrocytoma cell lines, neogenin mRNA expression is
within the same range as seen in normal brain regions.
This diverse expression pattern in brain tumors is not
unexpected because both overexpression and repression
of neogenin have been previously reported in neoplastic
tissues [30,31]. The function of neogenin in the adult
brain tissue remains to be determined.
In the brain, the highest expression levels for TfR1 mRNA
were in the medulla oblongata and the hippocampus, and
expression was distinctly lower in the cortex, thalamus,
and cerebellum (Fig. 3). The brain tumors had no differ-
ential expression of TfR1 mRNA compared to normal
human cortex. However, the astrocytoma cell lines had
substantially higher TfR1 expression than the brain
tumors. These differences in TfR1 expression levels agree
with the expression intensities and patterns observed in a
previous study [32]. The cerebellum was the only part of
the normal brain expressing TfR2 mRNA (Fig. 4). Some
TfR2 mRNA expression was present in a few brain tumor
specimens, with possible differential expression in oli-
goastrocytomas. TfR2 mRNA was not expressed in astrocy-
toma cell lines.
The HFE gene encodes a MHC type 1-like protein that is
involved in modulating iron homeostasis [33,34]. We
observed that HFE mRNA was expressed at low levels in
human cortex, cerebellum, and thalamus, but not in
medulla oblongata or hippocampus (Fig. 5). Brain tumors
and astrocytoma cell lines showed somewhat higher
expression of HFE mRNA than normal cortex. The highest
mRNA levels were present in 3 out of 4 meningioma spec-
imens. Mutations in the HFE gene result in the most com-
mon form of hereditary hemochromatosis. Interestingly,
some studies suggest that one of the most common HFE
mutations, H63D, may be a genetic modifier for increased
risk of Alzheimer's disease and amyotrophic lateral sclero-
sis [35-37].
Although investigation of the molecular basis of iron
homeostasis has been intensive after the discovery of the
HFE gene in 1996 [34], little is still known about the role
of iron and iron-related genes in the brain. In this study,
we show that many of the genes considered essential for
the regulation of iron homeostasis outside the CNS are
also expressed in the brain. Iron regulation in the brain is
complex, and in future studies it will be of great interest to
investigate the protein expression of these molecules inPage 5 of 9
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Neogenin mRNA expression in normal brain and brain tumors detected by real-time PCRFigure 2
Neogenin mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is nor-
malized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cor-
tex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to 
Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers 
in astrocytomas indicate tumor grade.
Transferrin receptor 1 mRNA expression in normal brain and brain tumors detected by real-time PCRFigur  3
Transferrin receptor 1 mRNA expression in normal brain and brain tumors detected by real-time PCR. The 
expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal 
brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered 
according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. 
**Roman numbers in astrocytomas indicate tumor grade.
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Transferrin receptor 2 mRNA expression in normal brain and brain tumors detected by real-time PCRFigur  4
Transferrin receptor 2 mRNA expression in normal brain and brain tumors detected by real-time PCR. The 
expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal 
brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered 
according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. 
**Roman numbers in astrocytomas indicate tumor grade.
HFE mRNA expression in normal brain and brain tumors detected by real-time PCRFigure 5
HFE mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is normal-
ized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cortex, 
Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to Table 1. 
Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers in astro-
cytomas indicate tumor grade.
BMC Neuroscience 2009, 10:36 http://www.biomedcentral.com/1471-2202/10/36different brain regions along with assessment of regional
iron concentrations. Due to the presence of the blood-
brain barrier, the CNS can adjust its iron status somewhat
independently of other organs. Our results also indicate
that the expression pattern of iron-related genes can vary
markedly in tumors arising within the brain. Further
investigation will be required to evaluate whether the dys-
regulated expression of iron-related genes in brain tumors
may contribute to tumor pathogenesis.
Conclusion
The present study describes the expression of several iron-
related genes including hepcidin (HAMP), HFE, neo-
genin(NEO1), transferrin receptor 1 (TFRC), transferrin
receptor 2 (TFR2), and hemojuvelin(HFE2) in normal
human brain, brain tumors, and astrocytoma cell lines.
Our results suggested that all these genes except for HFE2
are expressed in the normal brain, and that their expres-
sion may be dysregulated in certain brain tumors.
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